A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
about
P1343
Managing risks in drug discovery: reproducibility of published findingsReproducibility: changing the policies and culture of cell line authenticationThe Walker 256 Breast Cancer Cell- Induced Bone Pain Model in RatsHigh-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistanceFunctional DNA repair signature of cancer cell lines exposed to a set of cytotoxic anticancer drugs using a multiplexed enzymatic repair assay on biochipSNP detection in mRNA in living cells using allele specific FRET probesA highly sensitive and specific system for large-scale gene expression profilingNovel Algorithms for the Identification of Biologically Informative Chemical Diversity Metrics.Cell lines authentication and mycoplasma detection as minimun quality control of cell lines in biobankingCytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharumExpression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions.Recombination phenotypes of the NCI-60 collection of human cancer cells.pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristicsQuantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer.Short tandem repeat profiling: part of an overall strategy for reducing the frequency of cell misidentificationDoxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancerExpression of microRNAs in the NCI-60 cancer cell-linesTumorspheres but not adherent cells derived from retinoblastoma tumors are of malignant origin.Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Analysis of TP53 mutation status in human cancer cell lines: a reassessmentGenotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines.Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growthPrior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumoursSNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cellsCalcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells.Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness.A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells.Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.Therapeutic potential of RNA interference in drug-resistant cancers.Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.Authentication of human cell-based products: the role of a new consensus standard.Breast cancer biomarker measurements and standards.
P2860
Q24289508-BF957AFE-E735-4AC7-9313-E391DA5A2944Q27910523-0FC97BF4-F76E-4D1C-9CA7-FEA2214A117CQ28075980-84C182BA-5847-40ED-A292-7D52C7FE63F5Q28474284-629C5A52-47AD-4201-93B4-42FF22317739Q28484673-3E8B74E7-D0B8-42F1-B8DB-A1B80584DC7AQ28536974-D6B6E6D6-785E-404E-921A-023848D4E1FCQ28755360-E2E219B4-06A6-471B-8559-D85AE8BD0190Q33507533-4276CD53-87D5-47BB-B9C2-F52F75E0548CQ33678702-A585DBAF-A691-437B-B6E3-133C468970D5Q33815674-C32A6450-1FE7-4763-9C42-3D35AE785CD5Q33874365-0647D922-37B8-44DE-983A-894CD9D9E54FQ33903479-A9CFA061-4DE8-4DEC-A88A-37FCCD165687Q34059878-7A00D342-D5EB-4CA4-B1C7-6722769EB9E1Q34267466-E04F1F19-F027-435B-9630-F400CC906F40Q34284396-4113892E-A5B5-40E0-9BCF-B40101B4750EQ34372921-2CCB10F7-D049-4654-80F5-A8918B3017AAQ34469733-4942CA66-10E3-4B9C-BEE1-77A3F8641251Q34499806-78BF6B82-FE7F-4850-9CF8-26B94BDEEE9DQ34795615-D5643617-0BD9-4FD9-B713-8A1F3969E9FEQ34996536-E5755019-2F6F-484E-AA0A-356816C3E618Q35057879-AC317171-37BD-4218-B9D7-784F0AC24939Q35671197-0B8009A8-3A0A-44E8-8AE7-FDEE91E7BDBBQ35796373-C78AFB09-2E00-448B-9D15-53095267DC83Q36011433-368B1120-9BD5-4250-A8BF-9D64A09D7D85Q36063561-88FB43D1-410D-41F3-9A45-16803567E442Q36621389-DE122AD7-62A5-4681-9411-D1A28152D0A3Q36633219-1F0F9726-7342-40A0-B765-487223C1A2A9Q36953719-573702D6-9776-4404-B311-6BF4EA31EDBFQ36976346-A64F6F11-35D6-4E96-8275-83A3E58553FEQ36985137-310B881E-3C17-4523-85F8-677ACBB0A13FQ37040640-9581EE6D-8FDB-4291-A165-3FDC9DB8AAEAQ37074644-DA6F1F1B-03B7-4079-B716-EDD9813641E0Q37091520-DB233718-9EEC-4F65-88B2-B153B2F15E25Q37109747-063576F4-566C-47F4-AA47-173D02582AA6Q37271116-E23F1885-D974-4701-AB1E-660C5A938F0CQ37414354-34B1D5DA-5D29-4D92-AEB5-B17EF1E81003Q37706632-FF7C7B13-B9C6-450F-A9F7-EFE6267CF13AQ37706969-36746A64-B0EF-4E13-8B4C-F13BD51B5BC0Q37851508-AB03BBAF-4C2B-4F83-9C52-DDBD3877A0F1Q38076082-5C56AEDE-66D1-4EDD-A32E-2A8EE0EEE0F3
P2860
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
A case study in misidentificat ...... human ovarian carcinoma cells.
@ast
A case study in misidentificat ...... human ovarian carcinoma cells.
@en
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells
@nl
type
label
A case study in misidentificat ...... human ovarian carcinoma cells.
@ast
A case study in misidentificat ...... human ovarian carcinoma cells.
@en
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells
@nl
prefLabel
A case study in misidentificat ...... human ovarian carcinoma cells.
@ast
A case study in misidentificat ...... human ovarian carcinoma cells.
@en
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells
@nl
P1433
P1476
A case study in misidentificat ...... human ovarian carcinoma cells.
@en
P2093
Dana Ravid
Mordechai Liscovitch
P304
P356
10.1016/J.CANLET.2006.01.013
P407
P4510
P577
2006-02-28T00:00:00Z